Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study

被引:91
|
作者
Ryu, S. Y. [1 ]
Kim, M. H. [1 ]
Nam, B. H. [2 ]
Lee, T. S. [3 ]
Song, E. S. [4 ]
Park, C. Y. [5 ]
Kim, J. W. [6 ]
Kim, Y. B. [7 ]
Ryu, H. S. [8 ]
Park, S. Y. [9 ]
Kim, K. T. [10 ]
Cho, C. H. [11 ]
Lee, C. [12 ]
Kim, S. M. [13 ]
Kim, B. G. [14 ]
Bae, D. S. [14 ]
Kim, Y. T. [15 ]
Nam, J-H [15 ]
机构
[1] Korea Inst Radiol & Med Sci, Korea Canc Ctr Hosp, Dept Obstet & Gynecol, Seoul 139706, South Korea
[2] Natl Canc Ctr, Res Inst & Hosp, Biometr Res Branch, Goyang 410769, Gyeonggi Do, South Korea
[3] SMG SNU Boramae Med Ctr, Dept Obstet & Gynecol, Seoul 156707, South Korea
[4] Inha Univ, Sch Med, Dept Obstet & Gynecol, Inchon 400711, South Korea
[5] Gachon Univ, Gil Med Ctr, Dept Obstet & Gynecol, Inchon 405760, South Korea
[6] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 110744, South Korea
[7] Seoul Natl Univ, Bundang Hosp, Dept Obstet & Gynecol, Songnam 463707, South Korea
[8] Ajou Univ, Sch Med, Dept Obstet & Gynecol, Suwon 443721, South Korea
[9] Natl Canc Ctr, Res Inst & Hosp, Ctr Uterine Canc, Goyang 410769, South Korea
[10] Inje Univ, Busan Paik Hosp, Dept Obstet & Gynecol, Pusan 614735, South Korea
[11] Keimyung Univ, Dongsan Med Ctr, Dept Obstet & Gynecol, Taegu 700712, South Korea
[12] Inje Univ, Sanggye Paik Hosp, Coll Med, Dept Obstet & Gynecol, Seoul 139707, South Korea
[13] Chonnam Natl Univ, Sch Med, Dept Obstet & Gynecol, Kwangju 501757, South Korea
[14] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul 135710, South Korea
[15] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Obstet & Gynecol, Seoul 138736, South Korea
关键词
cervical cancer; intermediate-risk group; four-factor model; PELVIC RADIATION-THERAPY; EARLY-STAGE; CARCINOMA; ADENOCARCINOMA; IB; RECURRENCE; HISTOLOGY; OUTCOMES; IMPACT;
D O I
10.1038/bjc.2013.716
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In this study, we sought to identify a criterion for the intermediate-risk grouping of patients with cervical cancer who exhibit any intermediate-risk factor after radical hysterectomy. Methods: In total, 2158 patients with pathologically proven stage IB-IIA cervical cancer with any intermediate-risk factor after radical hysterectomy were randomly assigned to two groups, a development group and a validation group, at a ratio of 3:1 (1620 patients:538 patients). To predict recurrence, multivariate models were developed using the development group. The ability of the models to discriminate between groups was validated using the log-rank test and receiver operating characteristic (ROC) analysis. Results: Four factors (histology, tumour size, deep stromal invasion (DSI), and lymphovascular space involvement (LVSI)) were significantly associated with disease recurrence and included in the models. Among the nine possible combinations of the four variables, models consisting of any two of the four intermediate-risk factors (tumour size >= 3 cm, DSI of the outer third of the cervix, LVSI, and adenocarcinoma or adenosquamous carcinoma histology) demonstrated the best performance for predicting recurrence. Conclusion: This study identified a 'four-factor model' in which the presence of any two factors may be useful for predicting recurrence in patients with cervical cancer treated with radical hysterectomy.
引用
收藏
页码:278 / 285
页数:8
相关论文
共 50 条
  • [1] Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study
    S Y Ryu
    M H Kim
    B H Nam
    T S Lee
    E S Song
    C Y Park
    J W Kim
    Y B Kim
    H S Ryu
    S Y Park
    K T Kim
    C H Cho
    C Lee
    S M Kim
    B G Kim
    D S Bae
    Y T Kim
    J-H Nam
    British Journal of Cancer, 2014, 110 : 278 - 285
  • [2] Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer
    Cao, Lijie
    Wen, Hao
    Feng, Zheng
    Han, Xiaotian
    Zhu, Jun
    Wu, Xiaohua
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 52 - 58
  • [3] Chemoradiation With Paclitaxel and Carboplatin in High-Risk Cervical Cancer Patients After Radical Hysterectomy: A Korean Gynecologic Oncology Group Study
    Lee, Taek Sang
    Kang, Soon Beom
    Kim, Young Tak
    Park, Byung Joo
    Kim, Yong Man
    Lee, Jong Min
    Kim, Seok Mo
    Kim, Young Tae
    Kim, Jae Hoon
    Kim, Kyung Tai
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (02): : 304 - 310
  • [4] Is Adjuvant Therapy Necessary for Patients with Intermediate-Risk Cervical Cancer after Open Radical Hysterectomy?
    Yahata, Hideaki
    Sonoda, Kenzo
    Inoue, Shusaku
    Yasutake, Nobuko
    Kodama, Keisuke
    Yagi, Hiroshi
    Yasunaga, Masafumi
    Ohgami, Tatsuhiro
    Onoyama, Ichiro
    Kaneki, Eisuke
    Okugawa, Kaoru
    Asanoma, Kazuo
    Kato, Kiyoko
    ONCOLOGY, 2020, 98 (12) : 853 - 858
  • [5] Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group
    Shigeta, Shogo
    Shimada, Muneaki
    Tsuji, Keita
    Nagai, Tomoyuki
    Tanase, Yasuhito
    Matsuo, Koji
    Kamiura, Shoji
    Iwata, Takashi
    Yokota, Harushige
    Mikami, Mikio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (09) : 1507 - 1515
  • [6] Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy
    Sun, Wenze
    Wang, Tao
    Shi, Fan
    Wang, Jiquan
    Wang, Juan
    Hui, Beina
    Zhang, Yingbing
    Lu, Jinli
    Chen, Hongwei
    Liu, Zi
    BMC CANCER, 2015, 15
  • [7] Significance of the Number of Intermediate-Risk Factors in Cervical Cancer Patients Treated with Radical Hysterectomy: A Retrospective Study of 976 Patients (Oct, 10.1080/08941939.2021.2013578, 2021)
    Zhang, Jingni
    Jiang, Peng
    Tu, Yuan
    Jiang, Shan
    Huang, Yuzhen
    Li, Ning
    Kong, Wei
    Yuan, Rui
    JOURNAL OF INVESTIGATIVE SURGERY, 2022, 35 (05) : 1196 - 1196
  • [8] The baseline recurrence risk of patients with intermediate-risk cervical cancer
    Yoneoka, Yutaka
    Kato, Mayumi Kobayashi
    Tanase, Yasuhito
    Uno, Masaya
    Ishikawa, Mitsuya
    Murakami, Takashi
    Kato, Tomoyasu
    OBSTETRICS & GYNECOLOGY SCIENCE, 2021, 64 (02) : 226 - 233
  • [9] Heterogeneous treatment effects of adjuvant therapy for patients with cervical cancer in the intermediate-risk group
    Taguchi, Ayumi
    Kato, Kosuke
    Hara, Konan
    Furusawa, Akiko
    Nakajima, Yujiro
    Ishizawa, Chihiro
    Tanikawa, Michihiro
    Sone, Kenbun
    Mori, Mayuyo
    Shimada, Muneaki
    Okamoto, Aikou
    Takekuma, Munetaka
    CANCER MEDICINE, 2023, 12 (18): : 18557 - 18567
  • [10] Impact of the care provided by gynecologic oncologists on outcomes of cervical cancer patients treated with radical hysterectomy
    Wu, Miao-fang
    Li, Jing
    Lu, Huai-wu
    Wang, Li-juan
    Zhang, Bing-zhong
    lin, Zhong-qiu
    ONCOTARGETS AND THERAPY, 2016, 9 : 1361 - 1370